A new report co-authored by Manhattan Institute senior fellow Benjamin Zycher, and Joseph DiMasi, and Christopher-Paul Milne, researchers from the Tufts Center for the Study of Drug Development, examines case histories for thirty-five important pharmaceutical innovations. Skeptics of the private industry assert that the development of new medicines is most attributable to publicly funded sources.
As Marcia Angell, former editor-in-chief of The New England Journal of Medicine, remarked during an interview with PBS News : "Innovation comes mainly from NIH-supported research in academic medical centers. The drug companies do almost no innovation."
In this new study, the authors debunk this assertion and argue that the private sector plays a critical role in drug development.
Key findings include:
The authors conclude that NIH-sponsored and private-sector drug research are complementary to one another and are equally necessary in order to provide patients with better care and treatment.
Benjamin Zycher, Ph.D., is a Senior Fellow at the Manhattan Institute's Center for Medical Progress. He writes extensively on economic and political effects of government regulation and taxation. His research interests include health care policy and the pharmaceutical sector. Benjamin Zycher is available to discuss this report and matters relating to economics and public expenditures.
Joseph A. DiMasi, Ph.D., is Director of Economic Analysis at the Tufts Center for the Study of Drug Development at Tufts University. His research interests include drug development and regulatory review processes, the impact of policies and practices to speed the development and review processes for new drugs, as well as other matters relating to the economics of the pharmaceutical industry.
Christopher--Paul Milne, D.V.M., M.P.H., J.D., is Associate Director at the Tufts Center for the Study of Drug Development at Tufts University. His research interests include the role of outsourcing in drug development, issues relating to the research and development of new treatments, specifically those for serious and life--threatening illnesses, rare disorders and conditions, and neglected diseases of the developing world. He also studies regulatory and policy initiatives related to the Critical Path Initiative.
Cite This Page: